Calidi Biotherapeutics Inc (AMEX:CLDI) does about 157.72K shares in volume on a normal day but saw 5504346 shares change hands in the recent trading day. The company now has a market cap of 8.81M USD. Its current market price is $1.09, marking an increase of 29.76% compared to the previous close of $0.84. The 52 week high reached by this stock is $29.30 whilst the lowest price level in 52 weeks is $0.80. The script in recent trading has seen the stock touch a high of $9 and a low of $2.
Calidi Biotherapeutics Inc (CLDI) has a 20-day trading average at $1.0697 and the current price is -96.28% off the 52-week high compared with 35.98% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.1527 and its 200-day simple moving average is $3.4976. If we look at the stock’s price movements over the week, volatility stands at 29.71%, which decreases to 13.46% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.52 to suggest the stock is neutral.
The consensus objective for the share price is $6.25, suggesting that the stock has a potential upside of 82.56% over the period. The median price target is 80.18% away from the current levels at $5.5.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 22, 2023 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $11.
The current price level is 1.90%, -5.44%, and -68.84% away from its SMA20, SMA50, and SMA200 respectively, with the CLDI price moving above the 50-day SMA on current market day. Calidi Biotherapeutics Inc (CLDI) stock is down -10.66% over the week and -9.92% over the past month. Its price is -92.78% year-to-date and -95.83% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -1.4 above consensus estimates by 0.3. The company’s next earnings report forecasts estimating quarterly EPS at -0.85 and -3.97 for whole year.
Its 12-month price target is $5.5. To reach the target analysts have set, the stock logically needs to grow 82.56 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $2, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $9.
Outstanding shares total 8.08M with insiders holding 22.78% of the shares and institutional holders owning 3.08% of the company’s common stock. The company has a return on equity of -238.50%. The beta has a value of 0.60.
